Interim Estimate of Vaccine Effectiveness of BNT162b2 (Pfizer-BioNTech) Vaccine in Preventing SARS-CoV-2 Infection Among Adolescents Aged 12–17 Years — Arizona, July–December 2021
Supporting Files
Public Domain
-
-
-
Series:
File Language:
English
Details
-
Journal Article:Morbidity and Mortality Weekly Report (MMWR)
-
Description:The BNT162b2 (Pfizer-BioNTech) mRNA COVID-19 vaccine has demonstrated high efficacy in preventing infection with SARS-CoV-2 (the Virus that causes COVID-19) in randomized placebo-controlled Phase III trials in persons aged 12-17 years (referred to as adolescents in this report) (1); however, data on real-word vaccine effectiveness (VE) among adolescents are limited (1-3). As of December 2021, the Pfizer-BioNTech vaccine is approved by the Food and Drug Administration (FDA) for adolescents aged 16-17 years and under FDA emergency use authorization for those aged 12-15 years. In a prospective cohort in Arizona, 243 adolescents aged 12-17 years were tested for SARS-CoV-2 by reverse transcription-polymerase chain reaction (RT-PCR) each week, irrespective of symptoms, and upon onset of COVID-19-like illness during July 25-December 4, 2021; the SARS-CoV-2 B.1.617.2 (Delta) Variants was the predominant strain during this study period. During the study, 190 adolescents contributed fully vaccinated person-time (≥14 days after receiving 2 doses of Pfizer-BioNTech vaccine), 30 contributed partially vaccinated person-time (receipt of 1 dose or receipt of 2 doses but with the second dose completed <14 days earlier), and 66 contributed unvaccinated person-time. Using the Cox proportional-hazards model, the estimated VE of full Pfizer-BioNTech vaccination for preventing SARS-CoV-2 infection was 92% (95% CI = 79%-97%), adjusted for sociodemographic characteristics, health information, frequency of social contact, mask use, location, and local Virus circulation. These findings from a real-world setting indicate that 2 doses of Pfizer-BioNTech vaccine are highly effective in preventing SARS-CoV-2 infection among Arizona adolescents. CDC recommends COVID-19 vaccination for all eligible persons in the U.S. including persons aged 12-17 years.
-
Subjects:
-
DOI:
-
ISSN:0149-2195 (print) ; 1545-861X (digital)
-
Pubmed ID:34968373
-
Pubmed Central ID:PMC8736269
-
Document Type:
-
Place as Subject:
-
Pages in Document:5 pdf pages
-
Volume:70
-
Issue:51
-
Download URL:
-
File Type:
-
Collection(s):
-
Main Document Checksum:urn:sha-512:bf29cff92d44d0f88ef2504d645b766b04edf429b2e8349b89b2fc647e387253cfa0005a6b0c45a63b7de2e798ad229fded54b3376137353086a4ab4419248b1
Supporting Files
File Language:
English
CDC STACKS serves as an archival repository of CDC-published products including
scientific findings, journal articles, guidelines, recommendations, or other public health information authored or
co-authored by CDC or funded partners.
As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.
As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.
You May Also Like
COLLECTION
Morbidity and Mortality Weekly Report (MMWR)